Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6KJZ

Crystal structure of PDE4D catalytic domain complexed with compound 1

This is a non-PDB format compatible entry.
Summary for 6KJZ
Entry DOI10.2210/pdb6kjz/pdb
DescriptorcAMP-specific 3',5'-cyclic phosphodiesterase 4D, ZINC ION, MAGNESIUM ION, ... (5 entities in total)
Functional Keywordspde4 inhibitor, hydrolase
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight76668.13
Authors
Huang, Y.-Y.,He, X.,Luo, H.-B. (deposition date: 2019-07-23, release date: 2020-03-18, Last modification date: 2025-01-22)
Primary citationLiang, J.,Huang, Y.Y.,Zhou, Q.,Gao, Y.,Li, Z.,Wu, D.,Yu, S.,Guo, L.,Chen, Z.,Huang, L.,Liang, S.H.,He, X.,Wu, R.,Luo, H.B.
Discovery and Optimization of alpha-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
J.Med.Chem., 63:3370-3380, 2020
Cited by
PubMed Abstract: To validate PDE4 inhibitors as novel therapeutic agents against vascular dementia (VaD), 25 derivatives were discovered from the natural inhibitor α-mangostin (IC = 1.31 μM). Hit-to-lead optimization identified a novel and selective PDE4 inhibitor (IC = 17 nM), which adopted a different binding pattern from PDE4 inhibitors roflumilast and rolipram. Oral administration of at a dose of 10 mg/kg exhibited remarkable therapeutic effects in a VaD model and did not cause emesis to beagle dogs, indicating its potential as a novel anti-VaD agent.
PubMed: 32115956
DOI: 10.1021/acs.jmedchem.0c00060
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.20000094865 Å)
Structure validation

248335

PDB entries from 2026-01-28

PDB statisticsPDBj update infoContact PDBjnumon